Novel therapies with demonstrated efficacy in advanced urothelial carcinoma such as immunotherapeutics and nectin‐4 targeting may, in the future represent a safer and more effective perioperative strategy.41, 42, 43. This evidence concerns the gene NECTIN4 and urothelial carcinoma.